Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microe...

Full description

Bibliographic Details
Main Authors: Katsunobu Hagihara, Stephen Chan, Li Zhang, David Y. Oh, Xiao X. Wei, Jeffry Simko, Lawrence Fong
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:OncoImmunology
Subjects:
th1
cd8
prostate cancer
checkpoint inhibition
resistance
immunomonitoring
therapeutic vaccination
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1486953

Internet

http://dx.doi.org/10.1080/2162402X.2018.1486953

Similar Items